Entries by m16Dev

FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide

The recently FDA-approved GENOSYL® inhaled nitric oxide may have pulmonary and antiviral benefits in treating pulmonary hypertension and acute infectious diseases associated with the novel coronavirus1 GENOSYL® DS facilitates outpatient use of inhaled nitric oxide in the treatment of cardiopulmonary symptoms associated with COVID-19   March 26, 2020 – VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company […]

VERO Biotech Announces First Patient With COVID-19 Infection Complicating Pulmonary Hypertension Treated with GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide

Treatment informs FDA approval for emergency expanded access use for GENOSYL® inhaled nitric oxide GENOSYL® DS facilitates homebound use of inhaled nitric oxide in the treatment of pulmonary hypertension in patients with COVID-19 infection March 24, 2020, – VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company focused on saving lives, alleviating suffering, and improving the […]

VERO Biotech, Leaders in the Development of Innovative Technologies for Inhaled Nitric Oxide Delivery, to Present at Biotech Showcase 2020

Prestigious investor conference runs concurrently with 38th Annual J.P. Morgan Healthcare Conference Atlanta, January 10, 2020, – VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company focused on saving lives, alleviating suffering and improving the healthcare economics, is pleased to announce it will be presenting at Biotech Showcase 2020. Biotech Showcase 2020 will take place concurrently with the […]

VERO Biotech Receives US FDA Approval of GENOSYL® for the Delivery of Inhaled Nitric Oxide

The GENOSYL® inhaled nitric oxide approval represents the first and only FDA-approved tankless delivery system and is an important new development in the clinical application of inhaled nitric oxide. FOR IMMEDIATE RELASE Contact: Ray Russo (908) 313-7172 Ray.Russo@VERO-biotech.com December 20, 2019, – VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company focused on saving lives, alleviating suffering […]

AARC 2018

We will be attending the 2018 AARC Congress in Las Vegas on December 4-7 2018. Come and visit our booth to learn about the great things happening at VERO Biotech!

VERO Biotech Names Michael Gentile as Vice President of Medical Affairs

For Immediate Release Contact: Ray Russo (908) 313 -7172 Ray.Russo@VERO-biotech.com Atlanta-based biotech company expands with addition of renowned Duke University School of Medicine and Health System respiratory and critical care expert. October 5, 2018, Atlanta, GA – VERO Biotech LLC, a biopharmaceutical company focused on the design, development and commercialization of next generation inhaled nitric […]

Biotech Firm Opens 15,585 SF Headquarters at Georgia Tech’s Technology Enterprise Park in Atlanta

ATLANTA —VERO Biotech has opened a new 15,585-square-foot headquarters at the Georgia Institute of Technology’s Technology Enterprise Park in Atlanta. The biopharmaceutical company, formerly known as GeNO LLC, designs, develops and commercializes products for patients with pulmonary and cardiac diseases. VERO Biotech will move its administrative, research & development and manufacturing departments from its current […]

VERO Biotech Moves HQ to Atlanta

The biotechnology company left Florida for the Peach State, setting up shop in a 15,600-square-foot space at Georgia Tech’s Technology Enterprise Park. Atlanta has reeled in another headquarters tenant. VERO Biotech recently wrapped up the relocation of its home base from Cocoa, Fla., to Georgia Tech’s Technology Enterprise Park (TEP) in Midtown Atlanta. VERO Biotech has […]